Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer

Alexandra Lapeyre-Prost; Marine Hug de Larauze; Benoist Chibaudel; Marie Line Garcia; Veronique Guering-Meyer; Olivier Bouché; Eveline Boucher; Marc Ychou; Jérôme Dauba; Stéphane Obled; Astrid Lièvre; David Malka; Roger Faroux; Isabelle Bonnet; Julien Taieb; Thierry André

doi:10.1016/j.clcc.2015.11.004

Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer

Alexandra Lapeyre-Prost, Marine Hug de Larauze, Benoist Chibaudel, Marie Line Garcia, Veronique Guering-Meyer, Olivier Bouché, Eveline Boucher, Marc Ychou, Jérôme Dauba, Stéphane Obled, Astrid Lièvre, David Malka, Roger Faroux, Isabelle Bonnet, Julien Taieb, Thierry André

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

The use of a central venous access device (CVAD) for adjuvant XELOX (capecitabine, oxaliplatin) does not appear to be justified for all cases of stage III colon cancer. The feasibility of XELOX without a CVAD in the adjuvant setting for stage III patients was evaluated. Our results confirm the feasibility of this approach in 81.2% of patients for whom a CVAD was not placed before the first chemotherapy cycle. Background 5-Fluorouracil and leucovorin plus oxaliplatin (FOLFOX) or capecitabine plus oxaliplatin (XELOX) is a standard adjuvant treatment for patients with stage III colon cancer (CC). Capecitabine is an oral fluoropyrimidine, and administration of oxaliplatin does not necessarily require the insertion of a central venous access device (CVAD). We evaluated the feasibility of XELOX without a CVAD as adjuvant treatment in patients with stage III CC. Patients and Methods We retrospectively studied prospectively collected data from patients with stage III CC treated with XELOX in the International Duration Evaluation of Adjuvant Chemotherapy French trial. Patients were divided into 2 groups: those with a CVAD and those with peripheral venous access (PVA), including patients who had and had not had a CVAD at the first cycle of chemotherapy. Chemotherapy without a CVAD was considered feasible if the patient received all cycles of adjuvant therapy without it. Results A total of 203 patients were included: 86 (43%) in the PVA group and 116 (57%) in the CVAD group. Of the 85 patients in the PVA group (1 patient was not treated), 69 (81.2%) did not require the insertion of a CVAD. However, 16 (18.8%) required CVAD insertion owing to systematic delay of the initially planned CVAD before the second cycle of chemotherapy in 7, complications related to PVA usage in 5, a switch to the modified FOLFOX6 regimen in 2, and other reasons in 2. The oxaliplatin dose was similar in both groups regardless of the chemotherapy duration. XELOX without a CVAD was feasible for 81.2% of the patients for whom a CVAD had not been planned before chemotherapy and for 88.4% of patients for whom chemotherapy was planned without the use of a CVAD. Conclusion XELOX chemotherapy without a CVAD is a feasible approach for treating patients with stage III CC in the adjuvant setting.

Original language	English
Pages (from-to)	250-256
Number of pages	7
Journal	Clinical Colorectal Cancer
Volume	15
Issue number	3
DOIs	https://doi.org/10.1016/j.clcc.2015.11.004
State	Published - 1 Sep 2016
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2015 Elsevier Inc.

Funding

The authors thank the patients, their caregivers, and all the study investigators listed: Albert Aleba (Centre Hospitalier Niort, Niort), Jean-Baptiste Bachet (Groupe Hospitalier Universitaire Pitié Salpetrière, Paris), Julien Baudon (Centre Hospitalier de Cholet, Cholet), Isabelle Baumgaertner (Centre Hospitalier Universitaire Henri Mondor, Creteil), Yves Becouarn (Institut Bergonié, Bordeaux), Nathalie Bonichon-Lamichhane (Clinique Tivoli, Bordeaux), Christian Borel (Centre Régional de Lutte Contre le Cancer Paul Strauss, Strasbourg), Karine Bouhier Leporrier (Centre Hospitalier Universitaire Côte de Nacre, Caen), Gilles Breysacher (Hôpital Louis Pasteur, Colmar), Jérôme Desrame (Hôpital Jean Mermoz, Lyon), Françoise Desseigne (Centre Léon Berard, Lyon), Louis Maris Dourthe (Clinique Sainte Anne, Strasbourg), Olivier Dupuis (Clinique Victor Hugo, le Mans), Marie Pierre Galais (Centre François Baclesse, Caen), Dany Gargot (Centre Hospitalier Blois, Blois), François Ghiringhelli (Centre G. F. Leclerc, Dijon), Denis Golfain (Centre Hospitalier Général, Dreux), Michel Gozy (Clinique de l'Europe, Amiens), Nathalie Grossat (Centre Hospitalier Universitaire Albert Clarac, Fort de France), Véronique Guerin Meyer (Centre Paul Papin, Angers), Fanny Kayal (Centre Hospitalier Macon, Macon), Cédric Lecaille (Polyclinique Nord Aquitaine, Bordeaux), Christine Lefoll (Centre Hospitalier Lagny, Lagny), Cécile Leyronnas (Institut Daniel Hollard, Grenoble), Jean-Pierre Lotz (Hôpital Tenon, Paris), Laurent Mineur (Institut Sainte Catherine, Avignon), Laurent Mosser (Centre Hospitalier Jacques Puel, Rodez), Christian Platini (Centre Hospitalier Régional Metz-Thionville, Metz), Sandrine Oziel-Taieb (Institut Paoli Calmettes, Marseille), Arnaud Patenotte (Hôpital Robert Morlevat, Semur en Auxois), Mathieu Pawels (Centre Hospitalier d'Abbeville, Abbeville), Patricia Prost (Centre Hospitalier Fleyriat, Bourg en Bresse), Mohamed Ramdani (Centre Hospitalier Béziers, Beziers), Eric Terrebonne (Hôpital du Haut-Lévêque, Pessac), Anne Thirot-Bidault (Centre Hospitalier Universitaire Bicetre-Kremlin, Bicetre), Thomas Walter (Hôpital Edouard Herriot, Lyon). We thank Dr Magdalena Benetkiewicz (Groupe Coopérateur Multidisciplinaire en Oncologie) for her editorial assistance with the preparation of the manuscript. This study was funded by the National Cancer Clinical Research Programme 2009 and the French National Cancer Institute.

Funders	Funder number
Institut National du Cancer

Keywords

Adjuvant chemotherapy
CVAD
Colon cancer
Peripheral venous access
XELOX

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clcc.2015.11.004

Cite this

Lapeyre-Prost, A., Hug de Larauze, M., Chibaudel, B., Garcia, M. L., Guering-Meyer, V., Bouché, O., Boucher, E., Ychou, M., Dauba, J., Obled, S., Lièvre, A., Malka, D., Faroux, R., Bonnet, I., Taieb, J., & André, T. (2016). Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer. Clinical Colorectal Cancer, 15(3), 250-256. https://doi.org/10.1016/j.clcc.2015.11.004

@article{48a13e06983f4326a47fae8f1f8f7295,

title = "Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer",

abstract = "The use of a central venous access device (CVAD) for adjuvant XELOX (capecitabine, oxaliplatin) does not appear to be justified for all cases of stage III colon cancer. The feasibility of XELOX without a CVAD in the adjuvant setting for stage III patients was evaluated. Our results confirm the feasibility of this approach in 81.2% of patients for whom a CVAD was not placed before the first chemotherapy cycle. Background 5-Fluorouracil and leucovorin plus oxaliplatin (FOLFOX) or capecitabine plus oxaliplatin (XELOX) is a standard adjuvant treatment for patients with stage III colon cancer (CC). Capecitabine is an oral fluoropyrimidine, and administration of oxaliplatin does not necessarily require the insertion of a central venous access device (CVAD). We evaluated the feasibility of XELOX without a CVAD as adjuvant treatment in patients with stage III CC. Patients and Methods We retrospectively studied prospectively collected data from patients with stage III CC treated with XELOX in the International Duration Evaluation of Adjuvant Chemotherapy French trial. Patients were divided into 2 groups: those with a CVAD and those with peripheral venous access (PVA), including patients who had and had not had a CVAD at the first cycle of chemotherapy. Chemotherapy without a CVAD was considered feasible if the patient received all cycles of adjuvant therapy without it. Results A total of 203 patients were included: 86 (43%) in the PVA group and 116 (57%) in the CVAD group. Of the 85 patients in the PVA group (1 patient was not treated), 69 (81.2%) did not require the insertion of a CVAD. However, 16 (18.8%) required CVAD insertion owing to systematic delay of the initially planned CVAD before the second cycle of chemotherapy in 7, complications related to PVA usage in 5, a switch to the modified FOLFOX6 regimen in 2, and other reasons in 2. The oxaliplatin dose was similar in both groups regardless of the chemotherapy duration. XELOX without a CVAD was feasible for 81.2% of the patients for whom a CVAD had not been planned before chemotherapy and for 88.4% of patients for whom chemotherapy was planned without the use of a CVAD. Conclusion XELOX chemotherapy without a CVAD is a feasible approach for treating patients with stage III CC in the adjuvant setting.",

keywords = "Adjuvant chemotherapy, CVAD, Colon cancer, Peripheral venous access, XELOX",

author = "Alexandra Lapeyre-Prost and {Hug de Larauze}, Marine and Benoist Chibaudel and Garcia, {Marie Line} and Veronique Guering-Meyer and Olivier Bouch{\'e} and Eveline Boucher and Marc Ychou and J{\'e}r{\^o}me Dauba and St{\'e}phane Obled and Astrid Li{\`e}vre and David Malka and Roger Faroux and Isabelle Bonnet and Julien Taieb and Thierry Andr{\'e}",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2016",

month = sep,

day = "1",

doi = "10.1016/j.clcc.2015.11.004",

language = "אנגלית",

volume = "15",

pages = "250--256",

journal = "Clinical Colorectal Cancer",

issn = "1533-0028",

publisher = "Elsevier",

number = "3",

}

Lapeyre-Prost, A, Hug de Larauze, M, Chibaudel, B, Garcia, ML, Guering-Meyer, V, Bouché, O, Boucher, E, Ychou, M, Dauba, J, Obled, S, Lièvre, A, Malka, D, Faroux, R, Bonnet, I, Taieb, J & André, T 2016, 'Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer', Clinical Colorectal Cancer, vol. 15, no. 3, pp. 250-256. https://doi.org/10.1016/j.clcc.2015.11.004

TY - JOUR

T1 - Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer

AU - Lapeyre-Prost, Alexandra

AU - Hug de Larauze, Marine

AU - Chibaudel, Benoist

AU - Garcia, Marie Line

AU - Guering-Meyer, Veronique

AU - Bouché, Olivier

AU - Boucher, Eveline

AU - Ychou, Marc

AU - Dauba, Jérôme

AU - Obled, Stéphane

AU - Lièvre, Astrid

AU - Malka, David

AU - Faroux, Roger

AU - Bonnet, Isabelle

AU - Taieb, Julien

AU - André, Thierry

PY - 2016/9/1

Y1 - 2016/9/1

N2 - The use of a central venous access device (CVAD) for adjuvant XELOX (capecitabine, oxaliplatin) does not appear to be justified for all cases of stage III colon cancer. The feasibility of XELOX without a CVAD in the adjuvant setting for stage III patients was evaluated. Our results confirm the feasibility of this approach in 81.2% of patients for whom a CVAD was not placed before the first chemotherapy cycle. Background 5-Fluorouracil and leucovorin plus oxaliplatin (FOLFOX) or capecitabine plus oxaliplatin (XELOX) is a standard adjuvant treatment for patients with stage III colon cancer (CC). Capecitabine is an oral fluoropyrimidine, and administration of oxaliplatin does not necessarily require the insertion of a central venous access device (CVAD). We evaluated the feasibility of XELOX without a CVAD as adjuvant treatment in patients with stage III CC. Patients and Methods We retrospectively studied prospectively collected data from patients with stage III CC treated with XELOX in the International Duration Evaluation of Adjuvant Chemotherapy French trial. Patients were divided into 2 groups: those with a CVAD and those with peripheral venous access (PVA), including patients who had and had not had a CVAD at the first cycle of chemotherapy. Chemotherapy without a CVAD was considered feasible if the patient received all cycles of adjuvant therapy without it. Results A total of 203 patients were included: 86 (43%) in the PVA group and 116 (57%) in the CVAD group. Of the 85 patients in the PVA group (1 patient was not treated), 69 (81.2%) did not require the insertion of a CVAD. However, 16 (18.8%) required CVAD insertion owing to systematic delay of the initially planned CVAD before the second cycle of chemotherapy in 7, complications related to PVA usage in 5, a switch to the modified FOLFOX6 regimen in 2, and other reasons in 2. The oxaliplatin dose was similar in both groups regardless of the chemotherapy duration. XELOX without a CVAD was feasible for 81.2% of the patients for whom a CVAD had not been planned before chemotherapy and for 88.4% of patients for whom chemotherapy was planned without the use of a CVAD. Conclusion XELOX chemotherapy without a CVAD is a feasible approach for treating patients with stage III CC in the adjuvant setting.

AB - The use of a central venous access device (CVAD) for adjuvant XELOX (capecitabine, oxaliplatin) does not appear to be justified for all cases of stage III colon cancer. The feasibility of XELOX without a CVAD in the adjuvant setting for stage III patients was evaluated. Our results confirm the feasibility of this approach in 81.2% of patients for whom a CVAD was not placed before the first chemotherapy cycle. Background 5-Fluorouracil and leucovorin plus oxaliplatin (FOLFOX) or capecitabine plus oxaliplatin (XELOX) is a standard adjuvant treatment for patients with stage III colon cancer (CC). Capecitabine is an oral fluoropyrimidine, and administration of oxaliplatin does not necessarily require the insertion of a central venous access device (CVAD). We evaluated the feasibility of XELOX without a CVAD as adjuvant treatment in patients with stage III CC. Patients and Methods We retrospectively studied prospectively collected data from patients with stage III CC treated with XELOX in the International Duration Evaluation of Adjuvant Chemotherapy French trial. Patients were divided into 2 groups: those with a CVAD and those with peripheral venous access (PVA), including patients who had and had not had a CVAD at the first cycle of chemotherapy. Chemotherapy without a CVAD was considered feasible if the patient received all cycles of adjuvant therapy without it. Results A total of 203 patients were included: 86 (43%) in the PVA group and 116 (57%) in the CVAD group. Of the 85 patients in the PVA group (1 patient was not treated), 69 (81.2%) did not require the insertion of a CVAD. However, 16 (18.8%) required CVAD insertion owing to systematic delay of the initially planned CVAD before the second cycle of chemotherapy in 7, complications related to PVA usage in 5, a switch to the modified FOLFOX6 regimen in 2, and other reasons in 2. The oxaliplatin dose was similar in both groups regardless of the chemotherapy duration. XELOX without a CVAD was feasible for 81.2% of the patients for whom a CVAD had not been planned before chemotherapy and for 88.4% of patients for whom chemotherapy was planned without the use of a CVAD. Conclusion XELOX chemotherapy without a CVAD is a feasible approach for treating patients with stage III CC in the adjuvant setting.

KW - Adjuvant chemotherapy

KW - CVAD

KW - Colon cancer

KW - Peripheral venous access

KW - XELOX

UR - http://www.scopus.com/inward/record.url?scp=84952015220&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2015.11.004

DO - 10.1016/j.clcc.2015.11.004

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 26752558

AN - SCOPUS:84952015220

SN - 1533-0028

VL - 15

SP - 250

EP - 256

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

IS - 3

ER -

Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer

Abstract

Bibliographical note

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this